Product

Portfolio Intelligence Portside Congress trades Super-investors Economic calendar Earnings calendar Pricing

Company

About FAQs Contact Create account

Legal

Privacy Terms Portside rules

NRSN

NeuroSense Therapeutics Ltd.

COMMON STOCK · NASDAQ

Price and daily changeSign in

52-week rangeSign inDay rangeSign in

Market cap

Loading evidence for NRSN

Volume

Beta

Shares float

Short interest

1.44%

P/E (fwd)

PEG (fwd)

Rev growth (fwd)

Price chart (1D to 10Y)

Licensed market data — shown to members, not published to the open web.

Create free account

Overview Statistics Statements Dividends🔒Momentum🔒Quant🔒Fair Value🔒Earnings Analysts🔒Insiders Smart Money Options🔒Insights🔒

Trading information

Beta: Sign in
Shares outstandingAs of 2025-12-31 · filed common shares: 32.55M
Shares float: Sign in
Float %: Sign in
Insider ownershipDirectors and officers, from their latest Form 3/4/5 holding: 21.59%
Institutional ownership: Sign in
Short interestShare of shares outstanding, at settlement: 1.44%
Short ratioDays to cover, as published by FINRA: 1.46
Short volume (5D)Share of FINRA reporting-facility volume sold short, daily flow: 25.20%
Short volume (20D)Share of FINRA reporting-facility volume sold short, daily flow: 37.70%
Avg volume (10D)

See the full stock page

Prices, charts, ranges, valuation ratios, dividends, momentum and analyst estimates are licensed for signed-in members. A free account opens every stock, fund and crypto page.

Create free account

Source: SEC filings. Information and analytics, not investment advice.

Avg volume (3 months)

Profitability

Gross margin: —
Operating margin: —
Net margin: —
EBITDA margin: —
Return on equityNet income (FY Dec 25) ÷ average shareholders equity: -2174.98%
Return on assetsNet income (FY Dec 25) ÷ average total assets: -397.11%

Growth

Revenue growth (annual YoY): —
Revenue growth (latest qtr YoY): —
Revenue growth (fwd): Sign in
Net income growth (annual YoY): —
Net income growth (latest qtr YoY): —
EPS growth (fwd): Sign in
Net income growth (QoQ): —

Valuation

Market cap: Sign in
Enterprise value: Sign in
P/E: Sign in
P/E (fwd): Sign in
PEG: Sign in
PEG (fwd): Sign in
Price / book: Sign in
Price / sales

Price / operating cash flow

P/FCF

EV / revenue

EV / EBITDA

EPS

—

EPS (fwd)

Financial health

Cash & equivalentsas of Dec 25: $166.00K
Total cash: Sign in
Total debtBorrowings + finance and operating lease liabilities, as of Dec 25: $170.00K
Debt / equityas of Dec 25: -10.90%
Current ratioas of Dec 25: 0.31
Quick ratio: —
Operating cash flowFY Dec 25: -$7.67M
Free cash flowUnadjusted FCF = CFO − capex · FY Dec 25: -$7.67M
TTM revenue / diluted share: —

NRSN stock Statistics — NeuroSense Therapeutics Ltd. filings, insiders & smart money · Instaport